

**HONOURARY PROFESSOR ROBERT RAMSAY FROM PETER MAC
APPOINTED AS SCIENTIFIC ADVISOR**

MELBOURNE (AUSTRALIA) 16 December 2024: Invion Limited (ASX: IVX) ("**Invion**" or the "**Company**"), a clinical-stage biotechnology company focused on advancing the next-gen Photodynamic Therapy (**PDT**) for cancers and other serious diseases, is pleased to announce that Prof Robert Ramsay has been appointed as its Scientific Advisor to provide critical strategic guidance on Invion's upcoming clinical trials and research programs.

Prof Ramsay is an Honorary Professor at the Peter MacCallum Cancer Centre (**Peter Mac**) and was recently ranked by Stanford University to be in the top two per cent for career citations among the 100,000 most-cited scientists in the world¹.

Prof Ramsay is familiar with Invion's lead cancer drug candidate, INV043. He spearheaded the preclinical studies on INV043 at Peter Mac, which showed combination therapy with INV043 and immune checkpoint inhibitors (**ICIs**) *in vivo* led to circa 80% control of anal squamous cell carcinomas (**ASCC**), versus 12.5% when using ICIs alone², and is currently working with Peter Mac on bringing the results of these studies into an anogenital cancer clinical trial.

Commenting on his appointment, Prof Ramsay said:

"I am thrilled to be Scientific Advisor to Invion and help navigate its scientific and clinical trial programs to realise Photosoft™'s potential in treating multiple cancers. Our mission is to make this technology clinically relevant and address unmet needs in patient care."

"From the studies we have undertaken at Peter Mac, Photosoft™ holds the promise to become an alternative treatment for cancers, and it is exciting to see where this technology can take us."

About Professor Rob Ramsay

Prof Rob Ramsay is a globally recognised expert in cancer biology and translational medicine, with over 40 years of research experience. He has made significant contributions to the development of novel therapies in oncology. Prof Ramsay was Co-Head of the Gastrointestinal Program at Peter Mac, one of the world's leading cancer research and treatment facilities.

In addition to his role at Peter Mac, Prof Ramsay has a distinguished academic career, holding professorships in the Sir Peter MacCallum Department of Oncology and Department of Clinical Pathology at the University of Melbourne. He is a former President of the Australian Society for Medical Research (**ASMR**), National Assoc. of Research Fellows (**NARF**) and immediate past President of International Society for the Study of the Pleura and Peritoneum (**ISSPP**) and current board director of the Australasian Gastrointestinal Trials Group (**AGITG**) where he played an instrumental role in advancing medical research policy and clinical translation in Australia.

¹ <https://www.petermac.org/about-us/news-and-events/news/details/dozens-of-peter-mac-researchers-feature-in-stanford-university-s-worldwide-top-scientist-list2>

² <https://investors.inviongroup.com/announcements/6228975>

ASX ANNOUNCEMENT

Invion's Executive Chair and CEO, Thian Chew, commented:

"We are honoured to welcome Prof Ramsay to our team. His expertise in oncology and translational clinical research will be instrumental in guiding us forward. The opportunity to draw on his extensive experience will strengthen Invion's ability to deliver on our mission to bring life-changing therapies to patients around the world."

This announcement was approved for release by the Board of Directors.

Sign up at Invion's Investor Hub to receive regular updates, provide feedback and participate in discussions: <https://investors.inviongroup.com/>

Investor and Media enquiries:

Thian Chew (Chairman & CEO)
T: +61 3 9692 7222
E: investor@inviongroup.com

Brendon Lau (Investor & Media Relations)
M: +61 409 341 613
E: brendon.lau@inviongroup.com

About Invion

Invion is a life-science company that is leading the global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. It also holds the exclusive rights to the technology in Asia and Oceania, excluding China, Hong Kong, Taiwan, Macau, the Middle East and Russia for atherosclerosis and infectious diseases, and subsequently acquired the rights to the United States, Canada and Hong Kong for infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited. Invion is listed on the ASX (ASX: IVX).

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as a novel next generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has the potential to address the global challenge of antibiotic-resistant "superbugs".